Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4499968 | 0.82 | ALDH1A1 (0.43) | L3MBTL1MEN1KMT2ASTAT3MAPT | |
| SCHEMBL4494656 | 0.78 | CYP1A2 (0.50) | PPARDMEN1KMT2AMAPTMAPK1 | |
| SCHEMBL5016607 | 0.74 | ALDH1A1 (0.65) | L3MBTL1MEN1KMT2ASTAT3MAPT | |
| SCHEMBL4497526 | 0.72 | CYP2C19 (0.45) | PPARDKMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL5651517 | 0.72 | STAT3 (0.61) | MEN1KMT2ASTAT3MAPTLMNA | |
| SCHEMBL13713054 | 0.71 | AGTR1 (0.54) | L3MBTL1MEN1KMT2AMAPTLMNA | |
| SCHEMBL26674959 | 0.70 | L3MBTL1 (0.57) | L3MBTL1MEN1KMT2AMAPTLMNA | |
| SCHEMBL4502305 | 0.70 | PKM (0.47) | L3MBTL1PPARDMEN1KMT2AMAPT | |
| SCHEMBL4493011 | 0.70 | AGTR1 (0.51) | L3MBTL1MEN1KMT2AMAPTLMNA | |
| SCHEMBL4497374 | 0.69 | POLB (0.43) | MEN1KMT2AMAPTLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585883-B2 | Substituted pyridines and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585883-B2 | Substituted pyridines and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585883-B2 | Substituted pyridines and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1817303-A2 | SUBSTITUTED PYRIDINES WITH ACTIVITY ON SYK KINASE | Rigel Pharmaceuticals, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060178407-A1 | Substituted pyridines and their uses | RIGEL PHARMACEUTICAL, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006050480-A2 | SUBSTITUTED PYRIDINES WITH ACTIVITY ON SYK KINASE | RIGEL PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178407-A1 | Substituted pyridines and their uses | KIT, CPA3, CMA1 | L3MBTL1 4496/4885PPARD 1789/4885MEN1 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.